Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000254
Chunk: 33

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 33
---
 B.V. and Grace Systems B.V., which were acquired on February
13, 2024.

Renovaro Biosciences Overview

Renovaro
Biosciences is a biotechnology company intending, if the necessary funding
is obtained, to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term
or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human
Immunodeficiency Virus (HIV) infections. As a result of our acquisition of GEDi Cube Intl Ltd. on February 13, 2024, we have shifted the
Company’s primary focus and resources to the development of the Renovaro Cube technologies.

Therapeutic Technologies

Renovaro Biosciences aims to train the immune system to allow a person to better
fight diseases through allogeneic cell and/or gene therapy. Our vision is for a world with healthy longevity, and free from toxic chemotherapy,
for those with cancer and other serious diseases. Renovaro Biosciences will seek to leverage general principles and advances in the knowledge
of the immune response to engineer cells with enhanced attributes to promote the recognition and elimination of disease cells.

<div align='center'>20</div>

Allogeneic Cell Therapy

The strategic benefit of the allogeneic
cell therapy technologies is to potentially allow for the manufacture of large, “off-the-shelf” banks of therapeutic cells
that are readily available on demand by healthcare professionals, to potentially decrease the time between diagnosis and treatment.

In certain treatments (e.g., HIV
and cancer), cells taken from healthy donors are engineered to introduce signaling molecules that are designed to enhance the ability
of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.

Gene Therapy

Renovaro Biosciences may also seek
to explore various approaches for gene therapy design elements to potentially eliminate virus-infected or cancer cells by the modulation
of the patient’s immune system. Upon injecting into the patients, these genetically engineered allogeneic cells have little to no
risk of passing those modifications to the patient since they are terminally differentiated with locked functionality to activate the
host immune system. Gene modified allogeneic cells are expected to be rejected naturally once they activate the patient’s immune
system therefore will have a very short survival time.

Renovaro Biosciences Focus Areas:

Oncology: